OncoSec Medical Inc.

01/27/2021 | Press release | Distributed by Public on 01/27/2021 08:05

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein